News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 215010

Monday, 04/13/2015 1:31:33 AM

Monday, April 13, 2015 1:31:33 AM

Post# of 347009
Scott Antonia : Peregrine Pharmaceuticals KOL

"..it is surprising for lungcancer, we didn't expect it but clearly over the past 3 years lung cancer is an immunotherapeutically responsive cancer.."

"..the most exciting part about it is there are some people that have nice responses to these immunotherapeutics who are actually living for a very long time...so this is the first time we have been able to think about that, with people whom have advanced lung cancer, that people can live for a very long time with this disease.."

"..this is really just the beginning of an explosion of a large number of immunotherapeutics that are going to come along very..in rapid succession here in all having more and more activity here in this disease"

Now, I still find it very interesting that Dr. Scott Antonia has come on board with Peregrine Pharmaceuticals (as of Dec 10, 2013) just in the mix of this same 3 years timeframe where Dr. Antonia points out that immunotherapy is big and ready for an explosion ??

Well, not sure about you... but it sure sounds like Dr. Antonia just may be talking about PS Targeting and maybe it is PS Targeting that will be at the core of even allowing this explosion of activity to occur ?? Why? Well.. find me one other biotech that Dr. Antonia has joined over just this past 3 years?? I can't find one other besides Peregrine Pharmaceuticals and maybe, just maybe all the talk about 2016 or nothing will happen for 2 years or even Fool articles saying wait to make sure are all just part of the game and actually, would certainly make you a fool for standing by while you lose out on some big gains here.

Well, I'm ready to be proven wrong in hearing of other biotechs that Dr. Scott Antonia has joined in the past 3 years, because I'd sure like to know about them and with no others--- why did Dr. Scott Antonia hop on board with PPHM ?? What exactly has he seen and watch this interview again below, because it sure seems like PS Targeting is on his mind, the way he closes and says:

".. Understand these immunotherapeutics are not directed at the cancer...but really just allow your own immune system to kill your own cancer and in most people they have little or no side affects.."

http://www.patientpower.info/video/is-immunotherapy-making-lung-cancer-a-chronic-condition-for-some-patients

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y